View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsFresh2 Group 配当と自社株買い配当金 基準チェック /06Fresh2 Group配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 12Nasdaq to Delist ADS of Fresh2 GroupThe Nasdaq Stock Market announced that it will delist the American Depositary Shares of Fresh2 Group Limited. Fresh2 Group's stock was suspended on December 24, 2024 and has not traded on Nasdaq since that time.お知らせ • Apr 17+ 1 more updateHaohan Xu Resigns as Chief Executive Officer of Fresh2 Group Limited, Effective March 1, 2025Fresh2 Group Limited announced that Haohan Xu has resigned as Chief Executive Officer and Chairperson of the Board of Directors, effective March 1, 2025. Mr. Xu will continue to serve as a Director on the Company’s Board. The Company is in the process of evaluating candidates to fill the vacancy created by Mr. Xu’s departure and will make further announcements as appropriate.お知らせ • Dec 25Fresh2 Group Limited(NasdaqCM:FRES) dropped from NASDAQ Composite IndexAnPac Bio-Medical Science Co., Ltd. has been dropped from the NASDAQ Composite Index .New Risk • Nov 10New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (US$2.96m market cap). Minor Risk Revenue is less than US$5m (CN¥17m revenue, or US$2.4m).Board Change • Nov 04High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Member of Technical Advisory Board Lee Shulman is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 25Fresh2 Group Limited Announces Receipt of A Delinquency Compliance Alert Notice from NasdaqFresh2 Group Ltd. (Fresh2 or the Company) announced that on April 18, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission (the SEC), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the Rule), which requires the timely filing of all required periodic reports with the SEC. Nasdaq provided the Company 60 days to submit a plan to regain compliance with the Rule (the Plan). The Company intends to submit its plan of compliance to Nasdaq by June 17, 2024. If Nasdaq accepts the Plan, the Company may be granted an extension of 180 calendar days from the due date of the Form 10-K, or until October 14, 2024, to regain compliance with the Rule. In the event the Plan is not accepted by Nasdaq, the Company may appeal that decision to a Hearings Panel.お知らせ • Apr 03Fresh2 Group Limited announced delayed annual 10-K filingOn 04/02/2024, Fresh2 Group Limited announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 21Fresh2 Group Ltd Launches TikTok Video E-commerce Venture, Bridging the Gap Between Food Sources and ConsumersFresh2 Group Ltd. announced the launch of its video e-commerce venture on TikTok. This innovative venture marks a significant milestone in mission to revolutionize how consumers connect with food sources, bringing a fresh, dynamic approach to online shopping. Understanding the evolving consumer demand for transparency, quality, and value in building on the success of newly unveiled video e-commerce platform, Fresh2 is set to further enhance the shopping experience by introducing live food e-commerce in the near future. This ambitious expansion will offer an exclusive opportunity for consumers to engage directly with food sources like never before. By providing live broadcasts from food plants and farms, Fresh2 aims to open a window into the source of food production, offering transparency and trust in every purchase.お知らせ • Jan 30Fresh2 Group Receives Deficiency Notice from the Nasdaq Regarding Fails to Comply with the $1 Minimum Bid Price Required for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)On January 26, 2024, Fresh2 Group Limited (the ‘Company’) received a deficiency notice (the ‘Notice’) from The Nasdaq Stock Market (‘Nasdaq’) informing the Company that it failed to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the American Depositary Shares (‘ADSs’) of the Company for the 30 consecutive business days prior to the date of the Notice from Nasdaq. Nasdaq’s Notice has no immediate effect on the listing of the Company’s ADSs on The Nasdaq Capital Market. Pursuant to the Notice, the Company has been provided an initial compliance period of 180 calendar days, or until July 24, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the ADSs must meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to July 24, 2024. If the Company is unable to regain compliance by July 24, 2024, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the bid price requirement. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, Nasdaq will notify the Company of its determination to delist the ADSs, at which point the Company would have an opportunity to appeal the delisting determination to a Hearings Panel. The Company intends to monitor the closing bid price of the ADSs and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.お知らせ • Dec 16Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024Fresh2 Group Ltd. announced the appointment of Zhijun (Michael) Liang, as an independent director of the Company, effective January 1, 2024.Zhijun (Michael) Liang, has spent more than two decades providing management consulting and investment management services, primarily to start-ups and growth businesses, enabling them to address expansion needs and financial challenges. He co-founded Beijing Yuantong Funds Management Co. Ltd., and has led its risk and investment management since 2018. Concurrently, as the Managing Partner of Shanghai Tongdai Business Management Consulting LLP, he manages the firm's financial and management advisory services, dedicated to delivering premium solutions tailored to the unique needs of its clients.Mr. Liang holds an MBA degree in general management from HEC Montreal, the business school of the University of Montreal and a Bachelor of Arts degree in English Language and Literature from South-Central University for Nationalities (PRC).お知らせ • Aug 17+ 2 more updatesNingkasai Technology (Shanghai) Co., Ltd. entered into a share purchase agreement to acquire Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. from Fresh2 Group Limited (NasdaqCM:FRES) for CNY 1.Ningkasai Technology (Shanghai) Co., Ltd. entered into a share purchase agreement to acquire Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. from Fresh2 Group Limited (NasdaqCM:FRES) for CNY 1 on July 28, 2023. The closing is expected to take place within 30 days from the execution of the agreement.お知らせ • Jul 23Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy OfficerOn July 21, 2023, Fresh2 Group Limited appointed Mr. Yidong Hu as the Chief Strategy Officer of the Company, effectively immediately. Since 2009, Mr. Hu has served as the chairman of the board and the chief executive officer of Shenzhen Yinhetong Technology Co. Ltd. and SMI Holdings Group Limited, an investment holding company that operates theaters China and was previously listed on the Hong Kong Exchange. Mr. Hu obtained an EMBA degree from Graduate School of Tsinghua University and a bachelor’s degree in English from Linyi University in Shandong, China.お知らせ • Jun 13Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing RequirementsFresh2 Group Ltd., formerly AnPac Bio-Medical Science Co. Ltd. (NASDAQ: FRES), announced that The Nasdaq Stock Market LLC ('Nasdaq") notified the Company on June 9, 2023 that Nasdaq has determined the Company has regained compliance with the requirements to remain listed on The Nasdaq Capital Market, as required by the Hearing Panel's ("Panel") decision dated March 22, 2023. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from June 9, 2023. If, within that one-year monitoring period, Listing Qualifications staff ("Staff") finds the Company again out of compliance with the requirement that was the subject of the exception, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Hearings Panel is unavailable. The Company will have the opportunity to respond/present to the Panel as provided by Listing Rule 5815(d)(4)(C). The Company's securities may be at that time delisted from Nasdaq.お知らせ • May 18Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive OfficerFresh2 Group Limited announced that on May 17, 2023, Mr. Chris Chang Yu resigned as the Co-Chief Executive Officer of the company, effective immediately. Mr. Yu's resignation did not result from any disagreement with the Company or its management.お知らせ • Feb 10AnPac Bio-Medical Science Co., Ltd. (NasdaqCM:ANPC) entered into an agreement to acquire Fresh2 Ecommerce Inc for $2.1 million.AnPac Bio-Medical Science Co., Ltd. (NasdaqCM:ANPC) entered into an agreement to acquire Fresh2 Ecommerce Inc for $2.1 million on February 7, 2023. Pursuant to the SPA, the Company agreed to purchase 100% of the issued and outstanding equity interest of Fresh2 Ecommerce in consideration of $2,100,000, payable in the form of 5,440,420 newly issued Class A ordinary shares of the Company (or 272,021 American Depositary Shares or “ADSs”). The closing of the transaction is expected to take place in the first quarter of 2023.Seeking Alpha • Oct 18AnPac Bio announces plan to implement ADS ratio changeAnPac Bio (NASDAQ:ANPC) plans to change the ratio of the company’s American Depositary Shares to its Class A ordinary shares from one ADS representing one Class A ordinary share to one ADS representing twenty Class A ordinary shares. The change in the ADS ratio is expected to take place on November 4, 2022. For the company’s ADS holders, the change in the ADS ratio will have the same effect as a one-for-twenty reverse ADS split. The ADSs will continue to be traded on Nasdaq under the symbol “ANPC.” There will be no change to the company’s Class A ordinary shares. Shares are up 1.7% premarket.Seeking Alpha • Oct 03AnPac Bio-Medical Science announces management changesAnPac Bio-Medical Science (NASDAQ:ANPC) announces that Mr. Haohan Xu has been appointed as a director of the board of directors, Co-Chairperson of the Board and Co-CEO of the company. Mr. Xu is the CEO of Apifiny Group Ms. Xiaoyu Li has been appointed as a director of the Board and as CFO. Ms. Li has extensive experience in investor relations and investment. From May 2018 to August 2021, Ms. Li served as a director of Mercurity Fintech Holding Inc., where Ms. Li previously worked at the investor relations department from 2012 to 2013. Mr. Tianruo (Robert) Pu has been appointed as a director of theSeeking Alpha • Sep 27AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor GroupAnPac Bio-Medical Science (NASDAQ:ANPC) and a group of nine institutional and individual investors have signed legally binding pacts for the investment in the company of ~$3.67M to purchase 36.7M of the company’s Class A shares. It is expected that the investment will be completed in late September 2022.Board Change • Aug 10Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Feng Guo is the most experienced director on the board, commencing their role in 2018. Independent Director Jianhua Shao was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Seeking Alpha • Aug 05AnPac Bio appoints Yuyang Cui as co-chief executive officerAnPac Bio-Medical (NASDAQ:ANPC) said it had appointed Yuyang Cui as co-chairman of the board and co-chief executive officer of the company. Jiawen Kang has been appointed as a member of the board of directors of the Company and a member of the Audit Committee and Nominating Committee.Board Change • May 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Chairman Aidong Chen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 28Third quarter 2021 earnings: Revenues miss analyst expectationsThird quarter 2021 results: Revenue: -CN¥450.0k (down 106% from 3Q 2020). Net loss: CN¥12.6m (loss widened 2.8% from 3Q 2020). Revenue missed analyst estimates by 58%. Over the next year, revenue is forecast to grow 228%, compared to a 458% growth forecast for the industry in the US.Reported Earnings • Oct 17Second quarter 2021 earnings released: CN¥2.16 loss per share (vs CN¥3.15 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CN¥7.07m (up 126% from 2Q 2020). Net loss: CN¥28.0m (loss narrowed 20% from 2Q 2020).Major Estimate Revision • Jun 03Consensus revenue estimates fall to CN¥34.5mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CN¥41.2m to CN¥34.5m. Forecast losses increased from -CN¥2.81 to -CN¥4.28 per share. Biotechs industry in the US expected to see average net income decline 6.5% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 7.1% to US$4.30 over the past week.Reported Earnings • May 29First quarter 2021 earnings released: CN¥1.93 loss per share (vs CN¥2.56 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: CN¥2.19m (up 7.9% from 1Q 2020). Net loss: CN¥29.0m (loss widened 3.6% from 1Q 2020).Reported Earnings • May 03Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CN¥20.5m (up 89% from FY 2019). Net loss: CN¥80.5m (loss narrowed 20% from FY 2019).Is New 90 Day High Low • Feb 18New 90-day high: US$7.70The company is up 137% from its price of US$3.25 on 19 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.分析記事 • Dec 11Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%AnPac Bio-Medical Science Co., Ltd. ( NASDAQ:ANPC ) shareholders will have a reason to smile today, with the analysts...Is New 90 Day High Low • Nov 26New 90-day high: US$7.14The company is up 28% from its price of US$5.56 on 27 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.決済の安定と成長配当データの取得安定した配当: FREH.Yの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: FREH.Yの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Fresh2 Group 配当利回り対市場FREH.Y 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (FREH.Y)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.5%アナリスト予想 (FREH.Y) (最長3年)n/a注目すべき配当: FREH.Yは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: FREH.Yは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: FREH.Yの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: FREH.Yが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/02 17:43終値2025/11/20 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Fresh2 Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Theodore O'NeillLitchfield Hills Research, LLC
お知らせ • Jun 12Nasdaq to Delist ADS of Fresh2 GroupThe Nasdaq Stock Market announced that it will delist the American Depositary Shares of Fresh2 Group Limited. Fresh2 Group's stock was suspended on December 24, 2024 and has not traded on Nasdaq since that time.
お知らせ • Apr 17+ 1 more updateHaohan Xu Resigns as Chief Executive Officer of Fresh2 Group Limited, Effective March 1, 2025Fresh2 Group Limited announced that Haohan Xu has resigned as Chief Executive Officer and Chairperson of the Board of Directors, effective March 1, 2025. Mr. Xu will continue to serve as a Director on the Company’s Board. The Company is in the process of evaluating candidates to fill the vacancy created by Mr. Xu’s departure and will make further announcements as appropriate.
お知らせ • Dec 25Fresh2 Group Limited(NasdaqCM:FRES) dropped from NASDAQ Composite IndexAnPac Bio-Medical Science Co., Ltd. has been dropped from the NASDAQ Composite Index .
New Risk • Nov 10New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (US$2.96m market cap). Minor Risk Revenue is less than US$5m (CN¥17m revenue, or US$2.4m).
Board Change • Nov 04High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Member of Technical Advisory Board Lee Shulman is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 25Fresh2 Group Limited Announces Receipt of A Delinquency Compliance Alert Notice from NasdaqFresh2 Group Ltd. (Fresh2 or the Company) announced that on April 18, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission (the SEC), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the Rule), which requires the timely filing of all required periodic reports with the SEC. Nasdaq provided the Company 60 days to submit a plan to regain compliance with the Rule (the Plan). The Company intends to submit its plan of compliance to Nasdaq by June 17, 2024. If Nasdaq accepts the Plan, the Company may be granted an extension of 180 calendar days from the due date of the Form 10-K, or until October 14, 2024, to regain compliance with the Rule. In the event the Plan is not accepted by Nasdaq, the Company may appeal that decision to a Hearings Panel.
お知らせ • Apr 03Fresh2 Group Limited announced delayed annual 10-K filingOn 04/02/2024, Fresh2 Group Limited announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 21Fresh2 Group Ltd Launches TikTok Video E-commerce Venture, Bridging the Gap Between Food Sources and ConsumersFresh2 Group Ltd. announced the launch of its video e-commerce venture on TikTok. This innovative venture marks a significant milestone in mission to revolutionize how consumers connect with food sources, bringing a fresh, dynamic approach to online shopping. Understanding the evolving consumer demand for transparency, quality, and value in building on the success of newly unveiled video e-commerce platform, Fresh2 is set to further enhance the shopping experience by introducing live food e-commerce in the near future. This ambitious expansion will offer an exclusive opportunity for consumers to engage directly with food sources like never before. By providing live broadcasts from food plants and farms, Fresh2 aims to open a window into the source of food production, offering transparency and trust in every purchase.
お知らせ • Jan 30Fresh2 Group Receives Deficiency Notice from the Nasdaq Regarding Fails to Comply with the $1 Minimum Bid Price Required for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)On January 26, 2024, Fresh2 Group Limited (the ‘Company’) received a deficiency notice (the ‘Notice’) from The Nasdaq Stock Market (‘Nasdaq’) informing the Company that it failed to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the American Depositary Shares (‘ADSs’) of the Company for the 30 consecutive business days prior to the date of the Notice from Nasdaq. Nasdaq’s Notice has no immediate effect on the listing of the Company’s ADSs on The Nasdaq Capital Market. Pursuant to the Notice, the Company has been provided an initial compliance period of 180 calendar days, or until July 24, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the ADSs must meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to July 24, 2024. If the Company is unable to regain compliance by July 24, 2024, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the bid price requirement. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, Nasdaq will notify the Company of its determination to delist the ADSs, at which point the Company would have an opportunity to appeal the delisting determination to a Hearings Panel. The Company intends to monitor the closing bid price of the ADSs and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
お知らせ • Dec 16Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024Fresh2 Group Ltd. announced the appointment of Zhijun (Michael) Liang, as an independent director of the Company, effective January 1, 2024.Zhijun (Michael) Liang, has spent more than two decades providing management consulting and investment management services, primarily to start-ups and growth businesses, enabling them to address expansion needs and financial challenges. He co-founded Beijing Yuantong Funds Management Co. Ltd., and has led its risk and investment management since 2018. Concurrently, as the Managing Partner of Shanghai Tongdai Business Management Consulting LLP, he manages the firm's financial and management advisory services, dedicated to delivering premium solutions tailored to the unique needs of its clients.Mr. Liang holds an MBA degree in general management from HEC Montreal, the business school of the University of Montreal and a Bachelor of Arts degree in English Language and Literature from South-Central University for Nationalities (PRC).
お知らせ • Aug 17+ 2 more updatesNingkasai Technology (Shanghai) Co., Ltd. entered into a share purchase agreement to acquire Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. from Fresh2 Group Limited (NasdaqCM:FRES) for CNY 1.Ningkasai Technology (Shanghai) Co., Ltd. entered into a share purchase agreement to acquire Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. from Fresh2 Group Limited (NasdaqCM:FRES) for CNY 1 on July 28, 2023. The closing is expected to take place within 30 days from the execution of the agreement.
お知らせ • Jul 23Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy OfficerOn July 21, 2023, Fresh2 Group Limited appointed Mr. Yidong Hu as the Chief Strategy Officer of the Company, effectively immediately. Since 2009, Mr. Hu has served as the chairman of the board and the chief executive officer of Shenzhen Yinhetong Technology Co. Ltd. and SMI Holdings Group Limited, an investment holding company that operates theaters China and was previously listed on the Hong Kong Exchange. Mr. Hu obtained an EMBA degree from Graduate School of Tsinghua University and a bachelor’s degree in English from Linyi University in Shandong, China.
お知らせ • Jun 13Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing RequirementsFresh2 Group Ltd., formerly AnPac Bio-Medical Science Co. Ltd. (NASDAQ: FRES), announced that The Nasdaq Stock Market LLC ('Nasdaq") notified the Company on June 9, 2023 that Nasdaq has determined the Company has regained compliance with the requirements to remain listed on The Nasdaq Capital Market, as required by the Hearing Panel's ("Panel") decision dated March 22, 2023. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from June 9, 2023. If, within that one-year monitoring period, Listing Qualifications staff ("Staff") finds the Company again out of compliance with the requirement that was the subject of the exception, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Hearings Panel is unavailable. The Company will have the opportunity to respond/present to the Panel as provided by Listing Rule 5815(d)(4)(C). The Company's securities may be at that time delisted from Nasdaq.
お知らせ • May 18Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive OfficerFresh2 Group Limited announced that on May 17, 2023, Mr. Chris Chang Yu resigned as the Co-Chief Executive Officer of the company, effective immediately. Mr. Yu's resignation did not result from any disagreement with the Company or its management.
お知らせ • Feb 10AnPac Bio-Medical Science Co., Ltd. (NasdaqCM:ANPC) entered into an agreement to acquire Fresh2 Ecommerce Inc for $2.1 million.AnPac Bio-Medical Science Co., Ltd. (NasdaqCM:ANPC) entered into an agreement to acquire Fresh2 Ecommerce Inc for $2.1 million on February 7, 2023. Pursuant to the SPA, the Company agreed to purchase 100% of the issued and outstanding equity interest of Fresh2 Ecommerce in consideration of $2,100,000, payable in the form of 5,440,420 newly issued Class A ordinary shares of the Company (or 272,021 American Depositary Shares or “ADSs”). The closing of the transaction is expected to take place in the first quarter of 2023.
Seeking Alpha • Oct 18AnPac Bio announces plan to implement ADS ratio changeAnPac Bio (NASDAQ:ANPC) plans to change the ratio of the company’s American Depositary Shares to its Class A ordinary shares from one ADS representing one Class A ordinary share to one ADS representing twenty Class A ordinary shares. The change in the ADS ratio is expected to take place on November 4, 2022. For the company’s ADS holders, the change in the ADS ratio will have the same effect as a one-for-twenty reverse ADS split. The ADSs will continue to be traded on Nasdaq under the symbol “ANPC.” There will be no change to the company’s Class A ordinary shares. Shares are up 1.7% premarket.
Seeking Alpha • Oct 03AnPac Bio-Medical Science announces management changesAnPac Bio-Medical Science (NASDAQ:ANPC) announces that Mr. Haohan Xu has been appointed as a director of the board of directors, Co-Chairperson of the Board and Co-CEO of the company. Mr. Xu is the CEO of Apifiny Group Ms. Xiaoyu Li has been appointed as a director of the Board and as CFO. Ms. Li has extensive experience in investor relations and investment. From May 2018 to August 2021, Ms. Li served as a director of Mercurity Fintech Holding Inc., where Ms. Li previously worked at the investor relations department from 2012 to 2013. Mr. Tianruo (Robert) Pu has been appointed as a director of the
Seeking Alpha • Sep 27AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor GroupAnPac Bio-Medical Science (NASDAQ:ANPC) and a group of nine institutional and individual investors have signed legally binding pacts for the investment in the company of ~$3.67M to purchase 36.7M of the company’s Class A shares. It is expected that the investment will be completed in late September 2022.
Board Change • Aug 10Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Feng Guo is the most experienced director on the board, commencing their role in 2018. Independent Director Jianhua Shao was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Seeking Alpha • Aug 05AnPac Bio appoints Yuyang Cui as co-chief executive officerAnPac Bio-Medical (NASDAQ:ANPC) said it had appointed Yuyang Cui as co-chairman of the board and co-chief executive officer of the company. Jiawen Kang has been appointed as a member of the board of directors of the Company and a member of the Audit Committee and Nominating Committee.
Board Change • May 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & Chairman Aidong Chen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 28Third quarter 2021 earnings: Revenues miss analyst expectationsThird quarter 2021 results: Revenue: -CN¥450.0k (down 106% from 3Q 2020). Net loss: CN¥12.6m (loss widened 2.8% from 3Q 2020). Revenue missed analyst estimates by 58%. Over the next year, revenue is forecast to grow 228%, compared to a 458% growth forecast for the industry in the US.
Reported Earnings • Oct 17Second quarter 2021 earnings released: CN¥2.16 loss per share (vs CN¥3.15 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CN¥7.07m (up 126% from 2Q 2020). Net loss: CN¥28.0m (loss narrowed 20% from 2Q 2020).
Major Estimate Revision • Jun 03Consensus revenue estimates fall to CN¥34.5mThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from CN¥41.2m to CN¥34.5m. Forecast losses increased from -CN¥2.81 to -CN¥4.28 per share. Biotechs industry in the US expected to see average net income decline 6.5% next year. Consensus price target of US$8.00 unchanged from last update. Share price fell 7.1% to US$4.30 over the past week.
Reported Earnings • May 29First quarter 2021 earnings released: CN¥1.93 loss per share (vs CN¥2.56 loss in 1Q 2020)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: CN¥2.19m (up 7.9% from 1Q 2020). Net loss: CN¥29.0m (loss widened 3.6% from 1Q 2020).
Reported Earnings • May 03Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CN¥20.5m (up 89% from FY 2019). Net loss: CN¥80.5m (loss narrowed 20% from FY 2019).
Is New 90 Day High Low • Feb 18New 90-day high: US$7.70The company is up 137% from its price of US$3.25 on 19 November 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.
分析記事 • Dec 11Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%AnPac Bio-Medical Science Co., Ltd. ( NASDAQ:ANPC ) shareholders will have a reason to smile today, with the analysts...
Is New 90 Day High Low • Nov 26New 90-day high: US$7.14The company is up 28% from its price of US$5.56 on 27 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.